Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Research Council grant · Running

APOLLO-BC APOLLO-BC: Advanced Perfused platform for Breast Cancer therapy-response prediction

Coordinator
Universidade Nova De Lisboa, Portugal
Runs
1 October 2026 to 31 March 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101334669

What the project is doing

In the project's own words, from its summary on CORDIS.

The limited ability of preclinical models to predict clinical responses remains a major barrier in oncology drug development. Current systems used for cancer drug evaluation, including conventional 2D cultures and advanced 3D models such as patient-derived organoids (PDOs), fail to control key tumour microenvironment (TME) parameters that influence drug penetration, adaptive resistance, and therapeutic response, potentially limiting predictive accuracy.

Consequently, a gap persists between preclinical efficacy and clinical response, highlighting the need for ex vivo systems with improved predictive performance. Breast cancer provides a clinically relevant setting to address this challenge. Subtypes such as TNBC and HER2-positive disease show substantial variability in response to approved therapies, creating a need for improved methods to prioritise treatment options.

APOLLO-BC tests whether controlling key tumour microenvironment parameters, specifically perfusion and mechanical stiffness, improves the predictive accuracy of therapy-response ranking compared with PDO systems. The project will generate the first controlled direct comparative validation of a perfused, stiffness-controlled tumour model against conventional PDO workflows using matched patient-derived samples. A microfluidic platform integrating bioprinted 3D tumour constructs and real-time environmental monitoring will be standardised, followed by generation of matched TNBC and HER2+ models and a benchmarking study across ≥40 patients, each tested with ≥6 approved therapeutic regimens.

Reproducibility and predictive concordance with retrospective clinical outcomes will be quantitatively compared with PDO workflows. By generating rigorous comparative evidence, APOLLO-BC will determine whether microenvironmental engineering improves predictive drug-response assessment in breast cancer models, establishing a validated framework for next-generation functional oncology platforms.

Who is involved

OrganisationCityCountryRole
Universidade Nova De LisboaLisboaPortugalCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI